9th–10th February, 2027 | London, UK

www.cartcr-europe.com

FREE* FOR DRUG DEVELOPERS

10TH ANNIVERSARY

Europe CAR-TCR Summit

Uniting Science & Business Across the European Cell Therapy Community

Advancing *In Vivo* & Solid Tumour Cell Therapies to Drive Scalable Manufacturing, Clinical Excellence & Critical Investment

Expert Speakers Include:



Marc Davies
Vice President, R&D
Leucid Bio



Per Norlen
Chief Executive Officer
Strike Pharma



Anette Brass
Head of Process Development
Anocca



Angela Vollstedt
Director, Global R&D Cell & Gene Therapies Portfolio
Novartis



Anthea Wirges
Chief Executive Officer & Co-Founder
CARTemis Therapeutics



Simon Brack
Head of Strategic Analysis, External Scientific Innovation
Johnson & Johnson

Proud to Partner With:

Beacon · aldevron · octapharma · ProBio · SCINUS CELL EXPANSION

+44 (0)20 3141 8700 info@hansonwade.com
www.cartcr-europe.com CAR-TCR Summit Series
hansonwade

A Decade of Scientific Rigor, Commercial Vision & Transformative Progress

10th ANNIVERSARY CAR-TCR Summit Europe

9th–10th February, 2027 | London, UK

Welcome to the 10th Anniversary CAR-TCR Summit Europe

The cell therapy landscape is being reshaped by the rapid emergence of *in vivo* approaches, alongside renewed momentum behind *ex vivo* solid tumour therapies with the first landmark approval in June. At the same time, constrained investment continues to place greater emphasis on smart development decisions, strategic partnerships and efficient clinical execution. For Europe's cell therapy community, staying aligned with the companies defining the next chapter of the field has never been more important.

Celebrating its 10th anniversary, the **CAR-TCR Summit Europe** returns as the dedicated meeting place for senior CAR and TCR leaders to take part in a hyper-focused deep dive into the scientific, clinical and commercial strategies shaping the future of cell therapy. Designed to foster meaningful discussion, the summit's intentionally intimate format provides direct access to industry leaders, enabling deeper conversations, valuable knowledge exchange and stronger partnership opportunities.

Join executives, translational leaders, clinical developers and CMC decision makers from the likes of **AstraZeneca**, **Immatics**, **Leucid Bio** and **CPTX** for practical insights designed to help you seamlessly advance through the clinic.

What Our Speakers Have to Say

"The CAR-TCR Summit Europe is the peak event for our sector and the best place to keep up with what's what and who's who."

Chief Executive Officer, **OneChain**, 2027 Speaker


"I'm excited to learn about the latest advances in CAR-T and TCR therapies, particularly strategies to improve efficacy in solid tumours and translate next-generation approaches into successful clinical development."

Chief Medical Officer, **United Immunity**, 2027 Speaker

Here's What's New for Our 10th Year:



Increased *In Vivo* Innovation: Stay up to date on the fast-moving progress across *in vivo* development, covering complex gene engineering, scaling vector technology, and emerging data with **CPTX**, **Strike Pharma** and **OneChain Immunotherapeutocs**



New Track Focus Covering Preclinical Innovation, and Clinical and Manufacturing Development: Benchmark your pipeline against next generation innovations across solid tumours and autoimmune diseases, and move beyond technological innovation to pinpoint effective strategies to transform your clinical and commercial outcomes



Global Voices to Track Industry Advances: Connect with your European peers to tackle shared challenges and learn from a global faculty of key opinion leaders, leaving with a clear view of the direction of the cell therapy field




Free to Attend for Biopharma: We understand that focusing your cash on clinical development should be the priority. This year will be free to attend for the biopharma community, to ensure that this important forum is accessible to more of the cell therapy community

+44 (0)20 3141 8700 info@hansonwade.com
www.cartcr-europe.com CAR-TCR Summit Series
hansonwade

Celebrating 10 Years
of European CAR-TCR Innovation

10th ANNIVERSARY Europe CAR-TCR Summit
9th–10th February, 2027 | London, UK

Boasting an expanded representation of *in vivo* innovators and indications, explore the cell types, technologies and clinical advances defining the next chapter of cell therapy



New Data Sessions:

immatics	IMA203CD8 in Positive Solid Cancers
korecyte bio	Selectively & Safely Overcoming the Tumour Microenvironment to Reduce Barriers to Solid Tumour CAR-T Success
AANASTRA	Tailoring *In Vivo* Delivery Strategies for Autoimmune Disease Immunobiology
Leucid	Engineering Next-Generation CAR-T Cells for Improved Efficacy in Solid Tumours
STRIKE Pharma	Affinity Conjugation to Enable Personalized & Targeted LNP Delivery for *In Vivo* CAR Therapy

New Content Highlights:

Tap into the collective intelligence of the leaders defining cell therapy across *in vivo* delivery, overcoming the tumour microenvironment, economical manufacturing strategies, investment and partnerships and more. Through interactive sessions, data presentations and curated networking, access granular scientific and strategic insights to safely and economically accelerate your therapy through the clinic.

The Pivot from *Ex Vivo* to *In Vivo*
Tuesday, 9th February | 11.00m-12.30pm

As cell therapy innovation pushes into new territory, uncover how established *ex vivo* companies are building out their *in vivo* pipeline. Hear directly from the **T-Knife Therapeutics**, **One Chain Immunotherapeutics**, and **United Immunity** on how they incorporated *in vivo* therapies into their pipelines, equipping you to leverage your *ex vivo* knowledge to move your *in vivo* decisively through to clinic.

1

Highlighting CAR & TCR Globalisation: Why China, Why Now?
Tuesday, 9th February | 11.00am-12.30pm

One of the most significant shifts in cell therapy is unfolding beyond Europe's borders. Unpack why leading developers are looking East for manufacturing, clinical execution and innovation, and gain practical lessons from those successfully bridging China and the West to accelerate development, scale efficiently and bring therapies to patients faster.

2

Investment Insights Panel Discussion
Wednesday, 10th February | 9.00am-9.45am

Gain an inside view of the investment landscape directly from the investors backing the future of the field. Understand how to position your programme for maximum impact and take the conversation beyond the panel through meaningful face-to-face interactions with the decision makers whose support can transform the trajectory of your asset.

3

+44 (0)20 3141 8700 info@hansonwade.com
www.cartcr-europe.com CAR-TCR Summit Series
hansonwade

Your Global Expert Speaker Faculty

Future Focused Investors



Michael K Bauer
Partner
Novo Ventures AS



Tim Haines
Executive Partner & Managing Director
Abingworth

Industry-Leading C-Suite Executives



Gilles Divita
Chief Scientific Officer
Aanastra



Tim Oldham
Chief Executive Officer
Ad Alta



Blake Aftab
Chief Executive Officer
Adicet Bio



Cecile Bauche
Chief Scientific Officer
Alaya.Bio



Renaud Vallant
Co-Founder & President
Alaya.Bio



Samik Basu
Chief Scientific Officer
Cabaletta Bio



Anthea Wirges
Chief Executive Officer & Co-Founder
CARTemis Therapeutics



Edward Rebar
Chief Scientific Officer
CPTx



Johan Liwing
Chief Executive Officer
Elicera Therapeutics



Gregor Hutter
Founder & Chief Medical Officer
GlioCAR-T



John Bridgeman
Co-Founder & Chief Scientific Officer
Immunokey



James Arnold
Chief Scientific Officer
Korecyte Bio



Stefanos Theoharis
Chief Executive Officer
OneChain Immunotherapeutics



Per Norlen
Chief Executive Officer
Strike Pharma



Ulf Grawunder
Chief Executive Officer & Co-Founder
T-CURX



Peggy Sotiropoulou
Chief Scientific Officer
T-Knife Therapeutics



Kenji Hashimoto
Chief Medical Officer
United Immunity



Namir Hassan
Chief Executive Officer
Zelluna

Your Global Expert Speaker Faculty

Trend-Setting Biotechs



Anette Brass
Head of Process Development
Anocca



Matti Vanska
Senior Director, Clinical Development
AvenCell



Bryan Zimdahl
Senior Director, Clinical Science & Regulatory Affairs Legal
Eureka Therapeutics



Ali Mohamed
Senior Vice President, CMC
Immatics



Marc Davies
Vice President, R&D
Leucid Bio

Powerhouse Pharma



Anna Litsiou
Senior Director, Regulatory Policy & Intelligence, International Region
AstraZeneca



Simon Brack
Head of Strategic Analysis, External Scientific Innovation
Johnson & Johnson



Angela Vollstedt
Director, Global R&D Cell & Gene Therapies Portfolio
Novartis

Academics



Manel Juan
Head of Immunology
Hospital Clinic Barcelona

> "The networking was great, and the talks were very interesting. It was great to have a room of people interested in CAR-TCR"
>
> Senior Scientist, **Medicines & Healthcare products Regulatory Agency**, 2026 Attendee

> "This conference is very science focused. I value how you can just ask someone how something works and they always just tell you, which is something I don't find everywhere."
>
> Chief Scientific Officer, **Cabaletta Bio**, 2027 Speaker

Conference Day One
Tuesday, 9th February

7.30 Check-In & Coffee
Welcome to the 10th Anniversary CAR-TCR Summit Europe. Collect your badge, settle in with a coffee, and reconnect with the community before two days of learning, collaboration and partnerships.



Cecile Bauche
Chief Scientific Officer
Alaya.Bio

8.30 10th Anniversary Welcome Remarks

Spotlighting Transformative Advances to Shape the Future of the Field

8.45 Industry Leader's Fireside Chat: Aligning the Future of *In Vivo* & *Ex Vivo* Cell Therapies for Greater Clinical & Commercial Impact

- Reviewing how emerging clinical data is shaping market perspectives on *in vivo* cell therapies to guide smart pipeline decisions
- Examining the resurgence of next-generation *in vivo* CAR-Ts and *ex vivo* explorations for solid tumours and autoimmune disease to identify where each modality can unlock the greatest opportunity
- Aligning scientific, manufacturing, regulatory and commercial perspectives on the future direction of the field to accelerate clinical impact



Blake Aftab
Chief Executive Officer
Adicet Bio



Namir Hassan
Chief Executive Officer
Zelluna



Simon Brack
Head of Strategic Analysis, External Scientific Innovation
Johnson & Johnson



Cecile Bauche
Chief Scientific Officer
Alaya.Bio



Gregor Hutter
Founder & Chief Medical Officer
GlioCAR-T
NEW CLINICAL DATA

9.30 Keynote Presentation: Building Novel Dual-Action CAR-Ts to Effectively Balance Safety & Efficacy

- Highlighting dual-action CAR targeting the microenvironment and tumour cells
- Targeting macrophages to overcome immunosuppression in solid brain tumours
- Sharing emerging clinical data to evaluate the safety, efficacy, and reliability of CAR-T approaches

10.00 Coffee Break & Networking
As the community unites, gain valuable networking time with Europe's leading cell therapy experts, follow up with the morning's speakers for insights beyond the presentation slides and forge valuable new and lasting connections.

Preclinical Innovation

Leveraging *Ex Vivo* Therapeutic Success to Refine *In Vivo* Development Decision Making & Accelerate the Path to Clinic

11.00 Presentation Details to be Announced

Beacon

Clinical & Manufacturing Strategy

Harnessing Global Regulations & Manufacturing Opportunities to Efficiently Scale Cell Therapies

11.00 Accelerating Global Clinical Development Through Smarter Regulatory Strategy

- Navigating FDA, EMA, and NMPA expectations early to align development plans and enable smoother clinical progression
- Leveraging IND, CTA and IIT pathways to optimise streamline approvals, and reduce patient enrolment timelines
- Learning from successful global development programmes to identify regulatory strategies that have accelerated approvals, site activation, and clinical execution across major markets

Anna Litsiou, Senior Director, Regulatory Policy & Intelligence, International Region, **AstraZeneca**

Conference Day One
Tuesday, 9th February

11.30 Harnessing CAR-Macrophages to Overcome Solid Tumour Barriers *In Vivo*

- Exploring CAR-Macrophages as an alternative cell platform to overcome the limitations of CAR-T therapies in solid tumours
- Leveraging innate immune functions to penetrate the tumour microenvironment, enhance tumour infiltration, and drive durable responses
- Demonstrating the preclinical potential of *in vivo* cell therapy approaches to enhance accessibility for solid tumours

Kenji Hashimoto, Chief Medical Officer, **United Immunity**

IN VIVO

11.30 Harnessing the Best of East & West to Accelerate Global Cell Therapy Development

- Identifying the operational, strategic, and partnership frameworks required to leverage China's pace and cost advantages while meeting the expectations of global markets
- Designing manufacturing strategies that support scalable development, regulatory compliance, and seamless commercialisation across multiple geographies
- EW-001 armoured CAR-T case study highlighting regulatory considerations, operational efficiencies, and approaches to accelerate global development timelines

Tim Oldham, Chief Executive Officer, **Ad Alta**

12.00 Panel Discussion: Progressing *Ex Vivo* Success into Effective *In Vivo* Therapies

- Applying key learnings from *ex vivo* developments to optimise indication selection, targeting strategies, and clinical translation for *in vivo* approaches
- Discussing the key scientific, regulatory considerations to streamline the integration of *in vivo* cell therapies into the pipeline

Stefanos Theoharis, Chief Executive Officer, **OneChain Immunotherapeutics**

Peggy Sotiropoulou, Chief Scientific Officer, **T-Knife Therapeutics**

Ulf Grawunder, Chief Executive Officer & Co-Founder, **T-CURX**

12.00 Panel Discussion: Why China, Why Now? Evaluating the Opportunities, Risks & Realities of Operating in China

- Assessing the advantages and trade-offs of Chinese development and manufacturing, to determine the optimal balance between speed, cost, quality, effort, and long-term clinical strategy
- Navigating IIT pathways and regulatory requirements to support future clinical and regulatory success in Asia, the US and Europe
- Examining the investment and commercial implications of conducting trials and manufacturing in China, to accelerate asset interest and global market opportunities

Blake Aftab, Chief Executive Officer, **Adicet Bio**

Tim Oldham, Chief Executive Officer, **Ad Alta**

Anna Litsiou, Senior Director, Regulatory Policy & Intelligence, International Region, **AstraZeneca**

12.45 Lunch Break & Networking

Refuel over lunch while making the most of curated 1:1 meetings, available through our dedicated app. Connect directly with your key contacts and turn introductions into meaningful long-term relationships.

Engineering Cell Therapies to Combat the Tumour Microenvironment to Improve Long-Term Therapeutic Outcomes for Solid Tumour Therapies

1.45 Selectively & Safely Overcoming the Tumour Microenvironment to Reduce Barriers to Solid Tumour CAR-T Success

- Understanding solid tumour complexity and their microenvironment to enhance targeting and therapeutic outcomes
- Generating tumour-targeting immune cells tackling heterogeneity and immune suppression to overcome solid tumour defences
- Highlighting the precision and efficacy of HypoxiCAR in delivering highly potent payloads for neuroblastoma elimination

James Arnold, Chief Scientific Officer, **Korecyte Bio**

NEW DATA

Outlining Clinical Strategy for Emerging *In Vivo* & *Ex Vivo* Cell Therapies to Accelerate Clinical Approval

Matti Vanska, Senior Director, Clinical Development, **AvenCell**

1.45 Accelerating Solid Tumour Cell Therapy Development Through Adaptive Trial Design & Regulatory Strategy

- Optimising eligibility criteria and patient selection strategies to enhance clinical outcomes and accelerate development in solid tumours
- Leveraging adaptive trial designs and proactive regulatory engagement to streamline development pathways and support faster approvals
- Showcasing Phase II clinical data and key learnings to refine development strategies and advance next-generation solid tumour cell therapies

Bryan Zimdahl, Senior Director, Clinical Science & Regulatory Affairs Legal, **Eureka Therapeutics**

NEW DATA

Conference Day One
Tuesday, 9th February

2.15 Advancing Novel CAR Therapies Through a Comprehensive Discovery Engine

- Identifying novel solid tumour targets through bioinformatics-driven discovery to establish a strong foundation for CAR development
- Screening receptors and performing functional assays with patient-derived samples and in vitro models to select the optimal candidate for *in vivo* evaluation
- Evaluating data to select a candidate for preclinical development

John Bridgeman, Co-Founder & Chief Scientific Officer, **Immunokey**

NEW DATA

2.15 Translating an iTANK-Enhanced CAR-T into the Clinic to Expand Treatment Opportunities for Glioblastoma Patients

- Exploring how the iTANK platform is designed to enhance anti-tumour immune responses and address the immunosuppressive tumour microenvironment
- Reviewing the clinical rationale and development strategy underpinning the advancement of ELC-401 into patient evaluation
- Presenting early clinical experience with iTANK-enhanced CAR-T therapy and its potential to address significant unmet need in glioblastoma

Johan Liwing, Chief Executive Officer, **Elicera Therapeutics**



2.45 Afternoon Break & Poster Session

Contribute to the conversation and share your cutting-edge research with this community of cell therapy innovators while discovering exciting work carried out by your peers. To submit a poster, please contact info@hansonwade.com.

Boosting Novel Innovations to Deliver Safe Indication Expansion for Cell Therapies



Gilles Divita
Chief Scientific Officer
Aanastra

NEW DATA
IN VIVO

3.45 Tailoring *In Vivo* Delivery Strategies for Autoimmune Disease Immunobiology

- Evaluating how viral vectors, lipid nanoparticles and other delivery platforms interact with hyperactive innate and adaptive immune systems to minimise unwanted inflammatory responses
- Exploring how cytokine release, macrophage activation and dendritic cell responses differ across lupus, systemic sclerosis, myositis and other autoimmune indications to address disease-specific safety considerations
- Moving beyond a one-size-fits-all approach to develop indication-specific delivery and dosing strategies to improve therapeutic activity while reducing toxicity risks



Samik Basu
Chief Scientific Officer
Cabaletta Bio

4.15 Demonstrating Clinical Success in Autoimmune Disease Through Safe & Effective B-Cell Reset Strategies

- Defining B-cell reset to achieve meaningful disease remission across autoimmune indications
- Highlighting the mechanistic basis of the safety behind Cabaletta's rese-cel therapy to provide guidance on the development goals for autoimmune disease



Cecile Bauche
Chief Scientific Officer
Alaya.Bio

4.45 Chair's Closing Remarks



5.00 10th CAR-TCR Anniversary Drinks Reception

Raise a glass to a decade of progress, partnerships, and innovation at the 10th Anniversary CAR-TCR Summit Europe. Reconnect with the scientific and strategic business leaders who have defined the European CAR and TCR market, revisit the data the sparked debate and continue the discussion that simply count not fit into a Q&A.

6.00 End of Conference Day One

Conference Day Two
Wednesday 10th February

8.00 **Check-In & Coffee**
Kick off the final day of the conference with a coffee as you reignite valuable conversations from day one and spark new relationships.



Cecile Bauche
Chief Scientific Officer
Alaya.Bio

8.55 **Chair's Opening Remarks**

Aligning with Investors to Transform Innovation into Investment

9.00 **Panel Discussion: Uncovering Investor Priorities to Secure Cell Therapy Funding in 2027 & Beyond**

- Exploring the differences between European and US investment environments to optimise fundraising strategies
- Understanding the technologies, data packages and business models attracting investment to shape development strategies around evolving investor priorities
- Identifying strategies to differentiate from growing competition and build compelling investment cases that attract capital
- Discussing the future direction of the space to align with biotech innovation



Michael K Bauer
Partner
Novo Ventures AS



Tim Haines
Executive Partner & Managing Director
Abingworth



Renaud Vallant
Co-Founder & President
Alaya.Bio



Anthea Wirges
Chief Executive Officer
& Co-Founder
CARTemis Therapeutics

9.45 **Building a First-in-Class CXCR5-Targeting Cell Therapy to Overcome Relapse Through Dual Tumour & Microenvironment Targeting**

- Harnessing CXCR5 as a novel therapeutic target to address antigen escape while targeting tumorigenic cells and the tumour microenvironment
- Demonstrating the scientific rationale for CXCR5-directed therapies, including the elimination of both malignant B-cells and CXCR5-expressing TFH cells that contribute to disease persistence
- Sharing the latest preclinical progress across oncology and autoimmune indications and looking to the future for clinical development

10.15 **Morning Break & Networking**
Re-engage with highly sought-after investors through pre-arranged 1:1 meetings, deepen discussions around your strategy and funding needs and turn introductions into strategic partnership opportunities.

Preclinical Innovation

Optimising *In Vivo* Delivery Strategies to Enhance Targeting, Safety & Clinical Translation

11.15 Designing Selective Multi-Immune Cell Targeting LVVs with No Off-Target Delivery for *In Vivo* CAR-Ts Against Solid Tumours

- Engineering immune cell-targeted lentiviral vectors to enable selective *in vivo* CAR-T engineering while minimising off-target transduction and associated safety risks
- Targeting multiple immune cell types to combat solid tumours
- Advancing a next-generation *in vivo* platform to broaden patient access to transformative cell therapies

Stefanos Theoharis, Chief Executive Officer, **OneChain Immunotherapeutics**

IN VIVO

Clinical & Manufacturing Strategy

Advancing Smarter Manufacturing Strategies to Reduce Costs & Enable Sustainable Growth

11.15 Building Scalable TCR Manufacturing Strategies to Streamline Clinical Progression

- Designing manufacturing strategies to enable timely implementation/tech transfer of innovations
- Leveraging phase-appropriate automation to balance flexibility and scalability
- Understanding regulatory aspects that impact process design and innovation when progressing to later phases

Anette Brass, Head of Process Development, **Anocca**

Conference Day Two
Wednesday 10th February

11.45 Enabling *In Vivo* Cell Therapies to Combat Solid Tumours

- Exploring the specific challenges raised by solid tumours to *in vivo* cell therapy
- Designing approaches to all tackle key challenges
- Preclinical data demonstrating *in vivo* therapies for solid tumours

Peggy Sotiropoulou, Chief Scientific Officer, **T-Knife Therapeutics**

IN VIVO

11.45 Building Cost-Effective Solutions for Complex Manufacturing Processes

- Identifying the greatest cost drivers across development and manufacturing to proactively build a sustainable path to commercialisation
- Designing flexible manufacturing strategies to enable speed or COGs innovations that don't disrupt regulatory approval or proof of comparability
- Leveraging established pipelines to utilise similar CAR constructs across indications to reduce manufacturing changes, cost and regulatory push-back

Angela Vollstedt, Director, Global R&D Cell & Gene Therapies Portfolio, **Novartis**

12.15 Panel Discussion: Intelligently Pairing Vectors, Payloads & Engineering Technologies for *In Vivo* Cell Therapy Success

- Comparing viral and non-viral delivery approaches to understand how vector selection impacts safety, efficacy and cell-specific targeting
- Exploring advances in vector technology to successfully deliver DNA, mRNA and cRNA to unluck more durable expression with decreased therapeutic doses
- Developing scientifically guided frameworks to match delivery platforms, genetic cargo and tumour biology to accelerate translation to the clinic

Gilles Divita, Chief Scientific Officer, **Aanastra**

Edward Rebar, Chief Scientific Officer, **CPTx**

12.15 IMA203CD8 in Positive Solid Cancers

- Showcasing the manufacturing strategy behind IMA203 to meet the dosing demands of PRAME-positive solid tumours
- Connecting manufacturing innovation with clinical impact by enabling high-dose TCR therapies for solid tumours and supporting the advancement of emerging clinical data in next-generation cell therapies

Ali Mohamed, Senior Vice President, CMC, **Immatics**

NEW DATA

12.45 Lunch Break & Networking

Refuel over lunch while making the most of curated 1:1 meetings, available through our dedicated app. Connect directly with your key contacts and turn introductions into meaningful long-term relationships.

Showcasing Emergent Technologies to Enable *In Vivo* CAR-TCR Therapies

1.45 Utilising Non-Viral DNA Delivery to Define a Third Path for *In Vivo* CAR-T Therapies

- Exploring how single-stranded DNA delivery combines the advantages of non-viral manufacturing with the durability required for lasting therapeutic responses
- Showcasing emerging preclinical evidence supporting durable, relapse-resistant CAR-T therapies generated entirely through non-viral approaches

Edward Rebar, Chief Scientific Officer, **CPTx**

IN VIVO

2.15 Affinity Conjugation to Enable Personalised & Targeted LNP Delivery for *In Vivo* CAR Therapy

- Enabling attachment of personalised LNPs at the bedside
- Enhancing potency and efficacy of targeted LNPs to improve payload delivery and minimise off-target exposure
- Leveraging freeze-dried LNPs to simplify storage, distribution, and rapid bedside preparation
- Validated in mouse and NHP studies for both *in vivo* CAR-T and CAR-M

Per Norlen, Chief Executive Officer, **Strike Pharma**

NEW DATA

IN VIVO

Exploring Emerging Clinical & Manufacturing Designs to Decrease Unmet Patient Need While Producing Reliable Clinical Data

1.45 Introducing Point of Care Manufacturing Opportunities to Expand Patient Access to Cell Therapies

- Identifying the critical success factors for establishing a decentralised manufacturing network, including technology transfer, quality oversight, site readiness and partner selection
- Demonstrating how a point-of-care manufacturing model reduced treatment timelines and expanded patient access through a real-world implementation case study
- Exploring the network of point of care manufacturing

Manel Juan, Head of Immunology, **Hospital Clinic Barcelona**

2.15 Roundtable Discussion: Evaluating the Role of Hospital Exemptions & Point of Care Manufacturing to Expand Access Beyond Conventional CAR-T

- Exploring how regulations and appetite for both POC and hospital exemptions differ across the region to understand implementation feasibility across Europe
- Evaluating the long-term commercial viability of POC manufacturing, examining whether reduced logistics and turnaround times can outweigh quality control, regulatory and scalability challenges
- Defining what constitutes sufficient clinical evidence to support broader adoption, reimbursement and physician confidence in alternative CAR-T delivery models

Manel Juan, Head of Immunology, **Hospital Clinic Barcelona**

Conference Day Two
Wednesday 10th February

2.45 **Afternoon Networking & C -Level Think Tank**

Invitation Only Session

Step inside this closed-door discussion where Europe's senior executives unite to exchange hard-to access market intelligence, benchmark strategies and discuss the opportunities and challenges that will actively define the future of the cell therapy space.

Highlighting Innovations in Solid Tumour Therapies to Combat Unmet Patient Need



Marc Davies
Vice President, R&D
Leucid Bio
NEW UNPUBLISHED CLINICAL DATA

3.45 **Engineering Next-Generation CAR-T Cells for Improved Efficacy in Solid Tumours**

- Understanding immune biology to design tumour-specific CAR-T therapies
- Advancing construct innovations to deliver safe and effective outcomes for complex solid tumours
- Sharing emerging clinical data to validate novel solid tumour CAR-T approaches



Namir Hassan
Chief Executive Officer
Zelluna

4.15 **Unlocking the Potential of TCR-NK Therapy for Solid Tumours**

- Harnessing TCR specificity and NK-cell biology to create a differentiated approach to solid tumour targeting
- Reviewing preclinical evidence supporting anti-tumour activity, durability, and translational potential
- Sharing clinical progress and safety findings to highlight the therapeutic potential of TCR-NK therapies in patients



Cecile Bauche
Chief Scientific Officer
Alaya.Bio

4.45 **Chair's Closing Remarks & End of the 10th CAR-TCR Summit Europe**

"I found the talks interesting and particularly enjoyed access to clinical data"

Director, Early Oncology, **AstraZeneca**, 2026 Attendee

"I really enjoyed the opportunity to catch-up and network with those leading other biotechs focused on CAR & TCR therapies. The informal discussions can be very valuable."

Chief Executive Officer, **Pan Cancer T**, 2027 Speaker

A Community Unlike Any Other

10th ANNIVERSARY Europe CAR-TCR Summit

9th–10th February, 2027 | London, UK



Proactively **organise 1:1 meetings directly through our partnering app**. Secure face-to-face conversations with your top prospects, build interest in your services prior to day one, and arrive with qualified conversations, commercial opportunities and relationship-building already underway.



Present your expertise to a highly curated, **56% director+** audience of cell therapy leaders in our **Poster Session**. Use scientific credibility to open the doors that sales pitches can't, and connect with emerging biotech and future partners before they become the industry's next success stories.



Continue the conversations that matter most at the **10th Anniversary Drink's Reception** alongside the industry's leading academics, investors, biotech leaders and manufacturing pioneers. In this informal setting, access unfiltered perspectives and build the genuine relationships, trusted introductions and insider perspectives that create lasting competitive advantage.



Seamlessly exchange details with this diverse audience of *in vivo*, CAR and TCR leaders using our **in-app badge scanning** to nurture relationships beyond the event, stay close to evolving programmes, and position your business for future partnerships and commercial success.

2026 Attending Companies:

In Vivo

STRIKE Pharma · EsoBiotec · CPTx · OneChain Immunotherapeutics · korecyte bio · Alaya.bio

Ex Vivo CAR

glycostem · POLTREG · IASO Biotherapeutics · Autolus · Leucid · Cabaletta Bio

TCR

tknife Therapeutics · pan cancer T · zelluna Immunotherapy · anocca · immatics

Pharma

AstraZeneca · REGENERON · novo nordisk · Johnson & Johnson · NOVARTIS

Academia

Heidelberg University · Uppsala Universitet · CLÍNIC Barcelona Hospital Universitari · King's College London · Dresden University of Technology

> "Small-format meetings always facilitate discussions among participants and create a more friendly and interactive atmosphere. The high scientific level of most presentations, including clinical-phase data, provided broad insights into the different approaches."
>
> Study Director, **JC Discovery**, 2026 Sponsor

+44 (0)20 3141 8700 · info@hansonwade.com
www.cartcr-europe.com · CAR-TCR Summit Series
hansonwade

Take the Spotlight

10th ANNIVERSARY Europe CAR-TCR Summit

9th–10th February, 2027 | London, UK


Your Tailor-Made Platform to Foster New & Existing Relationships Within the CAR-TCR Community

Uncover the priorities shaping tomorrow's cell therapy landscape as you uncover the emerging needs and priorities of the industry's top pioneers. Gain the foresight needed to anticipate industry shifts, adapt your strategy earlier and engage customers around their future challenges rather than todays to secure partnerships for 2027 and beyond.

Emerge from the crowd and capitalise on European Biotech's growing demand for stability, scalability and access, highlighting your differentiated capabilities to cement yourself as the pivotal provider for cell therapy development

Move beyond lead generation and into face-to-face relationship-building with trailblazing developers to build champions for your organisation in critical outsourcing decisions and influence future purchasing decisions.


Seniority of Attendees



- Owner & CXO – 21%
- VP – 6%
- Director – 31%
- Manager – 22%
- Team Lead – 7%
- Academic – 7%
- Other – 6%

*Statistics taken from 9th CAR TCR Summit Europe

Type of Companies Attending



*Statistics taken from 11th CAR-TCR US with updated free to attend format

Get Involved



Hannah Martin
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

2027 Partners

Program Partner

Beacon Intelligence is a comprehensive and accurate drug development intelligence platform, offering unique technology and drug datasets for complex therapeutics and disease states. Leveraging proprietary ontologies and manually curated datasets, Beacon delivers unparalleled data, insights, analytics and workflow solutions to accelerate decisions at every stage of the drug development journey.

www.beacon-intelligence.com

Exhibition Partner

Aldevron is a premier manufacturing partner, producing plasmid DNA, RNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies, and other treatments. Headquartered in Fargo, North Dakota, and as a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people.

www.aldevron.com

Exhibition Partner

Octapharma are the world's largest privately owned plasma fractionator, with over 40 years of experience in the industry. Octapharma produce a range of GMP grade plasma derived proteins and serum media additives for the Life Sciences sector. Suitable for Cell & Gene Therapy, Vaccine Development, RNA/DNA Therapeutics, In Vitro Diagnostics, Immunoassays, and wider CDMO/CRO/CMO usage.All proteins are GMP grade, produced to a medicinal standard, and double-pathogen reduced. Bespoke and tailored regulatory documents can also be supplied to support approval body submission where material is listed as an excipient.With several concentrations available for each product, we can confidently support small-scale laboratory use, right through to end product manufacture, supporting all paces of company scale-up.

www.octapharma.co.uk

Exhibition Partner

ProBio, a subsidiary of GenScript, is a global CDMO offering end-to-end services from discovery to GMP for plasmids, antibodies, and cell and gene therapies. We bring together multidisciplinary expertise to accelerate development and manufacturing through customised, and comprehensive services.

www.probiocdmo.com

Event Partner

Scinus Cell Expansion Netherlands B.V. (Scinus) is an established partner in cell therapy and regenerative medicine, with a strong track record in translating cell culture processes into robust, GMP-compliant manufacturing workflows. Our Osilaris™ platform is a closed, GMP-ready bioreactor system designed for real-world production needs. As one of the most versatile bioreactor platforms, Osilaris™ supports adherent cells, suspension cells, and organoids in a single reactor. Its patented, single-use, volume-expandable culture bags enable high scale in a single run with a homogenised, ultra-low-shear environment. Osilaris™ also provides real-time monitoring and remote access for DO/pH control within a compliant GMP workflow, so you can run, monitor, and optimise cultures from anywhere with confidence.

www.scinus.com

Ready to Register?

3 Easy Ways to Book

www.cartcr-europe.com/register

Tel: +44 (0)20 3141 8700

Email: info@hansonwade.com

DIVE into the granular science underpinning the future of cell therapy, from *in vivo* CAR-Ts across haematological cancers, solid tumours and immunology to *ex vivo* solid tumour and autoimmunity innovations to refine your development strategy and accelerate your pipeline development.

TAP into an unrivalled network of pioneers, technical experts and industry leaders to access intelligence, relationships to remain ahead of the market.

ENGAGE with experts across drug discovery, clinical development, regulations, investments, manufacturing and trial management to pressure-test every facet of your strategy and build conviction around your scientific and commercial decisions.

Drug Developer, Academic & Not-for-Profit Pricing*	
Conference Only	Free to Attend (£0.50)

*To qualify, your organization must have a publicly available pipeline and not provide solutions or services for a fee to any other company, or be a full time academic

*Please note that credit card details will be taken upon registration, and a nominal fee of £0.50 charged.

Free access is only granted once approval of eligibility is confirmed. Hanson Wade retain the right to reject or cancel your registration if eligibility criteria are not met, and paid registration will then be required to access the event.

Hanson Wade reserves the right to charge free access guests a non-refundable charge of £100 if they do not attend the entire event if they fail to give 7 working days' notice of non-attendance.

If you are a UK or EU-based company, you may be subject to 20% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout. * To be eligible for this price, the group or individuals must be from a biotech or pharma company that has a publicly available pipeline, and does not offer pay for services. ** To be eligible for this price, the group or individual must be full-time academic(s).

Service & Solution Providers**	Register & Pay By Friday, December 18	On The Door
Conference Only	£3,399	£3,899

**All employees from CDMO, CRO, software, analytical, imaging, apheresis or clinical service provider, who partner with and provide services to, drug developers and/or research organisations

Prices exclude any applicable taxes. VAT or other indirect taxes may apply depending on event location and tax status. Eligible business customers may provide a valid VAT registration number at checkout where a reverse charge mechanism is available.

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Novotel London West
1 Shortlands, Hammersmith, London W6 8DR
www.novotellondonwest.co.uk/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom